MedAssets (MDAS) Getting Somewhat Positive Media Coverage, Study Shows

News coverage about MedAssets (NASDAQ:MDAS) has trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MedAssets earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news stories about the technology company an impact score of 44.6710956374203 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

WARNING: “MedAssets (MDAS) Getting Somewhat Positive Media Coverage, Study Shows” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.com-unik.info/2017/11/01/medassets-mdas-getting-somewhat-positive-media-coverage-study-shows.html.

About MedAssets

MedAssets, Inc (MedAssets) provides technology-enabled products and services to healthcare organizations, including hospitals, health systems, non-acute healthcare providers, payers, other service providers and product manufacturers. The Company operates its business through two business segments: Spend and Clinical Resource Management (SCM) and Revenue Cycle Management (RCM).

Insider Buying and Selling by Quarter for MedAssets (NASDAQ:MDAS)

What are top analysts saying about MedAssets Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MedAssets Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit